INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
06 févr. 2024 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
30 janv. 2024 08h00 HE
|
INmune Bio, Inc.
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the...
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
02 janv. 2024 08h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
18 déc. 2023 16h01 HE
|
INmune Bio, Inc.
Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its...
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
29 nov. 2023 08h00 HE
|
INmune Bio, Inc.
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the...
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
27 nov. 2023 08h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the...
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
15 nov. 2023 09h00 HE
|
INmune Bio, Inc.
The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive. Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune...
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
01 nov. 2023 16h10 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
31 oct. 2023 08h00 HE
|
INmune Bio, Inc.
INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent...
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
30 oct. 2023 09h07 HE
|
INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...